Guariguata L, Whiting DR, Hambleton I, et al: Global estimates of diabetes prevalence for 2013 and projections for 2035. Diabetes Res Clin Pract 103: 137, 2014.
Stockl K, Vanderplas A, Tafesse E, et al: Costs of lower-extremity ulcers among patients with diabetes. Diabetes Care 27: 2129, 2004.
Driver VR, Fabbi M, Lavery LA, et al: The costs of diabetic foot: the economic case for the limb salvage team. JAPMA 100: 335, 2010.
Yazdanpanah L, Nasiri M, Adarvishi S: Literature review on the management of diabetic foot ulcer. World J Diabetes 6: 37, 2015.
Margolis DJ, Kantor J, Berlin JA. Healing of diabetic neuropathic foot ulcers receiving standard treatment. A meta-analysis. Diabetes Care 22: 692, 1999.
Edmonds M: Apligraf in the treatment of neuropathic diabetic foot ulcers. Int J Low Extrem Wounds 8: 11, 2009.
Marston WA, Hanft J, Norwood P, et al: The efficacy and safety of Dermagraft in improving the healing of chronic diabetic foot ulcers: results of a prospective randomized trial. Diabetes Care 26: 1701, 2003.
Wu SC, Marston W, Armstrong DG: Wound care: the role of advanced wound-healing technologies. JAPMA 100: 385, 2010.
Driver VR, Lavery LA, Reyzelman AM, et al: A clinical trial of Integra Template for diabetic foot ulcer treatment. Wound Repair Regen 23: 891, 2015.
Yao M, Attalla K, Ren Y, et al: Ease of use, safety, and efficacy of integra bilayer wound matrix in the treatment of diabetic foot ulcers in an outpatient clinical setting: a prospective pilot study. JAPMA 103: 274, 2013.
Richard JL, Martini J, Bonello Faraill MM, et al: Management of diabetic foot ulcers with a TLC-NOSF wound dressing. J Wound Care 21: 142, 2012.
Veves A, Sheehan P, Pham HT: A randomized, controlled trial of Promogran (a collagen/oxidized regenerated cellulose dressing) vs standard treatment in the management of diabetic foot ulcers. Arch Surg 137: 822, 2002.
Waycaster CR, Gilligan AM, Motley TA: Cost-effectiveness of becaplermin gel on diabetic foot ulcer healing: changes in wound surface area. JAPMA 106: 273, 2016.
Wieman TJ, Smiell JM, Su Y: Efficacy and safety of a topical gel formulation of recombinant human platelet-derived growth factor-BB (becaplermin) in patients with chronic neuropathic diabetic ulcers. A phase III randomized placebo-controlled double-blind study. Diabetes Care 21: 822, 1998.
Li Z, Guo S, Yao F, et al: Increased ratio of serum matrix metalloproteinase-9 against TIMP-1 predicts poor wound healing in diabetic foot ulcers. J Diabetes Complications 27: 380, 2013.
Yang C, Zhu P, Yan L, et al: Dynamic changes in matrix metalloproteinase 9 and tissue inhibitor of metalloproteinase 1 levels during wound healing in diabetic rats. JAPMA 99: 489, 2009.
Guillemin Y, Le Broc D, Segalen C, et al: Efficacy of a collagen-based dressing in an animal model of delayed wound healing. J Wound Care 25: 406, 2016.
Armstrong DG, Lavery LA, Harkless LB: Validation of a diabetic wound classification system. The contribution of depth, infection, and ischemia to risk of amputation. Diabetes Care 21: 855, 1998.
Dumont IJ, Lepeut MS, Tsirtsikolou DM, et al: A proof-of-concept study of the effectiveness of a removable device for offloading in patients with neuropathic ulceration of the foot: the Ransart boot. Diabet Med 26: 778, 2009.
Margolis DJ, Allen-Taylor L, Hoffstad O, et al: Diabetic neuropathic foot ulcers: the association of wound size, wound duration, and wound grade on healing. Diabetes Care 25: 1835, 2002.
Oyibo SO, Jude EB, Tarawneh I, et al: The effects of ulcer size and site, patient's age, sex and type and duration of diabetes on the outcome of diabetic foot ulcers. Diabet Med 18: 133, 2001.
Landry GJ, Silverman DA, Liem TK, et al: Predictors of healing and functional outcome following transmetatarsal amputations. Arch Surg 146: 1005, 2011.
Lavery LA, Armstrong DG, Wunderlich RP, et al: Risk factors for foot infections in individuals with diabetes. Diabetes Care 29: 1288, 2006.
Martins-Mendes D, Monteiro-Soares M, Boyko EJ, et al: The independent contribution of diabetic foot ulcer on lower extremity amputation and mortality risk. J Diabetes Complications 28: 632, 2014.
The number of people with diabetes is expected to reach 592 million in the year 2035. Diabetic foot lesions are responsible for more hospitalizations than any other complication of diabetes. The aims of this study were to examine for the first time a new biocompatible and biodegradable tridimensional collagen-based matrix, GBT013, in humans for diabetic foot ulcer wound healing and to evaluate its ease of use to better define a protocol for a future clinical trial. Seven adult patients with a diabetic foot ulcer of grade 1A to 3D (University of Texas Diabetic Wound Classification) were treated using GBT013, a new collagen-based advance dressing and were monitored in two specialized foot care units for a maximum of 9 weeks. Five of seven wounds achieved complete healing in 4 to 7 weeks. Nonhealed ulcers showed a significant reduction of the wound surface (>44%). GBT013 was well tolerated and displayed positive wound healing outcomes as a new treatment strategy of chronic foot ulcers in diabetic patients.